In addition, similar findings of relative clinical resistance to PD-1/PD-L1–targeting agents were noted in patients with liver metastases in melanoma, lung cancer, kidney cancer, and other tumor types.11,12,13,14,15,16 Two recent retrospective studies17,18 including more than 300 patients with solid tumors who received checkpoint blockade demonstrated that the presence of liver metastases was associated with worse PFS and overall survival regardless of tumor histology. The gene discussed is CD274; the disease is kidney cancer.